Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers (SSVS)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Venous Stasis Ulcers
Sponsor: RegeneRx Biopharmaceuticals, Inc.
Listed as NCT00832091, this PHASE2 trial focuses on Venous Stasis Ulcers and remains completed. Sponsored by RegeneRx Biopharmaceuticals, Inc., it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jul 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- RegeneRx Biopharmaceuticals, Inc.
- sigma-tau i.f.r. S.p.A.
For direct contact, visit the study record on ClinicalTrials.gov .